Ertapenem

Drug Profile

Ertapenem

Alternative Names: Ertapenem sodium; Invanz; L 749345; MK 0826; MK 826; ZD 4433

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer Merck & Co
  • Class Amides; Antibacterials; Benzoic acids; Carbapenems; Pyrrolidines; Small molecules; Sulfides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Community-acquired pneumonia; Intra-abdominal infections; Obstetric and gynaecological infections; Skin and soft tissue infections; Urinary tract infections

Most Recent Events

  • 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote ertapenem in South Korea for Bacterial infections
  • 01 Dec 2013 Merck Sharp & Dohme completes a phase III trial in Skin and soft tissue infections (in patients with diabetes mellitus) in China (NCT01370616)
  • 01 Sep 2011 Phase-III clinical trials in Skin and soft tissue infections (in patients with diabetes mellitus) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top